This analysis highlights treatment challenges for older adults with chronic lymphocytic leukemia, emphasizing comorbidities and clinical trial representation.
Introduction Chronic lymphocytic leukemia (CLL) primarily affects older adults, with a median age at diagnosis around 70 years. While targeted therapies have improved outcomes, treatment decisions in the elderly are complicated by comorbidities, fraility, and underrepresentation in clinical trials.
No takes yet. Share an insight, caveat, or question.
Puła et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: